Anne Wojcicki is the former CEO of 23andMe, Inc. She co-founded the company in 2006, three years after the first human genome was sequenced. Her goal was audacious: To help people access, understand and benefit from the human genome and fundamentally change healthcare in the process. Prior to founding 23andMe, Anne spent a decade on Wall Street investing in healthcare and felt frustrated by a system built around monetizing illness instead of incentivizing prevention. She wanted to flip that model on its head and build a business that helps people prevent illness rather than profit from it. Anne focused on empowering people with direct access to genetic information so that they could use their data to make decisions that could lower their risks for disease. Under her leadership, 23andMe created the only personal genetic test with FDA authorization to deliver health information directly to consumers.

Along with empowering consumers with health information, Anne wanted 23andMe to transform how research discoveries are made and revolutionize the development of treatments for disease. By inviting people to participate in research, 23andMe crowdsources billions of data points resulting in the world’s largest resource for genetic research. This novel, web-based approach has already resulted in thousands of new genetic insights and allows 23andMe to rapidly recruit participants to multiple studies at once, reducing the time and resources needed to make discoveries and is integral to their mission of understanding and benefiting from the human genome This new approach to research also powers their therapeutics group, which helps to translate this knowledge into new treatments for serious unmet medical needs. In line with this, 23andMe is now also using its unique model to speed recruitment for clinical trials.

Anne graduated from Yale University with a BS in Biology.